Clinical Trial Update: Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

This report summarizes a completed dose-escalation Phase 1/2 trial of patupilone given every three weeks in patients with non-small cell lung cancer, focusing o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Patupilone (epothilone B)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2011-07-07